高血压起始两药固定剂量联合治疗与单药治疗的早期心血管保护比较
基于意大利伦巴第大区医疗数据库,2010年起始降压治疗(单药或两药固定剂量联合)的40-80岁居民随访1年,比较心血管住院风险。两药固定剂量联合治疗较单药治疗降低1年任何心血管事件住院风险21%(P<0.01),高维倾向评分匹配后降低15%(P<0.05)。在发生心血管事件的患者中,固定剂量联合治疗期间事件发生率较单药治疗期间降低56%(P<0.01)。
要点
- 高血压起始两药固定剂量联合治疗较单药治疗降低1年心血管住院风险21%。
- 倾向评分匹配后风险降低15%,自身对照分析显示联合治疗期间事件减少56%。
- 缺血性心脏病和初发房颤的住院风险降低始终显著。
核心结论
- 在真实世界中,高血压起始两药固定剂量联合治疗较单药治疗提供更有效的早期心血管保护。
研究设计与样本
- 采用高维倾向评分匹配和自身对照病例系列设计分析。
主要发现
- 与起始单药治疗相比,起始两药固定剂量联合治疗患者1年任何心血管事件住院风险降低21%(P<0.01)。
- 高维倾向评分匹配分析显示风险降低15%(P<0.05)。
- 在发生心血管事件的患者(n=2212)中,固定剂量联合治疗期间事件发生率较单药治疗期间降低56%(P<0.01)。
- 缺血性心脏病和初发房颤的住院风险降低始终显著。
- 自身对照分析中,脑血管疾病和心力衰竭住院风险降低也显著。
临床怎么用
- 高血压起始治疗可考虑两药固定剂量联合策略以更有效预防早期心血管事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Guidelines support use of drug combinations in most hypertensive patients, and recently treatment initiation with two drugs has been also recommended. However, limited evidence is available on whether this leads to greater cardiovascular (CV) protection compared to initial monotherapy. METHODS AND RESULTS: Using the healthcare utilization database of the Lombardy Region (Italy), the 44 534 residents of the region (age 40-80 years) who in 2010 started treatment with one antihypertensive drug (n = 37 078) or a two-drug fixed-dose combination (FDC, n = 7456) were followed for 1 year after treatment initiation to compare the risk of hospitalization for CV disease associated with the two treatment strategies. To limit the confounding associated with non-randomized between-group comparisons, data were also analysed by: (i) matching the two groups by the high-dimensional propensity score (HDPS) and (ii) comparing, in patients experiencing one or more CV events (n = 2212), the CV event incidence during subperiods in which patients were prescribed mono- or FDC therapy (self-controlled case series design). Compared to initial monotherapy, patients on initial FDC therapy showed a reduced 1 year risk of hospitalization for any CV event (-21%, P < 0.01). This was the case also when groups were compared according to the HDPS analysis (-15%, P < 0.05). Finally, in patients experiencing CV events, the event incidence was much less when, during the 1 year follow-up, they were under FDC therapy than under monotherapy (-56%, P < 0.01). The reduced risk of hospitalization was always significant for ischaemic heart disease and new onset atrial fibrillation, and included hospitalization for cerebrovascular disease and heart failure when monotherapy and FDC therapy were compared within patients. CONCLUSION: In a real-life setting, a comparison of the incidence of early CV events during antihypertensive monotherapy and FDC shows that the latter strategy leads to a more effective CV protection. This scores in favour of a two-drug FDC strategy as first step in the hypertensive population.
引用
- Rea F, Corrao G, Merlino L, et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018. PMID: 30060044. doi:10.1093/eurheartj/ehy420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。